Opus Genetics has officially treated the first participant in its Phase 1/2 clinical trial for OPGx-001 — a new gene therapy designed for individuals with LCA5-related Leber congenital amaurosis. This milestone marks the company’s first human trial and represents another important step forward in treating inherited retinal diseases. As more early-stage therapies enter clinical testing, hope continues to grow for families affected by progressive vision loss.

The Foundation Fighting Blindness has released four years of natural history data from its RUSH2A study, giving researchers open access to valuable insights into USH2A-related retinitis pigmentosa and Usher syndrome. This unprecedented data release is expected to accelerate clinical trial development and advance treatments for inherited retinal diseases.

Discover the story of paratriathlete Owen Cravens, who continues to compete, excel, and inspire despite vision loss from Stargardt disease. His determination and heart celebrate what’s possible for anyone facing retinal conditions.

This Thanksgiving week, we’re honoring the power of community gratitude through real reviews and experiences shared by supporters who have encouraged, uplifted, and inspired our family. These heartfelt messages—from donors, parents, and individuals living with visual challenges—remind us that we’re not walking this journey alone. Their compassion fuels our mission to advance sight-saving science for children like Luke.